SCHEMBL4473605

SCHEMBL4473605

CCN(CC)CCOc1ccc(C(=O)OC)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.70
LMNA P02545 1/20 0.67
SCN1A P35498 1/20 0.67
SCN2A Q99250 1/20 0.67
SCN3A Q9NY46 1/20 0.67
EBP Q15125 3/20 0.65
SIGMAR1 Q99720 3/20 0.65
RAB9A P51151 1/20 0.62
MCHR1 Q99705 3/20 0.61
BCHE P06276 1/20 0.56
ACHE P22303 1/20 0.56
ESR1 P03372 4/20 0.55
HRH3 Q9Y5N1 3/20 0.55
KCNH2 Q12809 2/20 0.55
CHRM2 P08172 2/20 0.55
ADRA2A P08913 2/20 0.55
ADORA3 P0DMS8 2/20 0.55
CHRM1 P11229 2/20 0.55
PTGS1 P23219 2/20 0.55
SLC6A2 P23975 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7246166 0.92 MAPT (0.68) MAPTLMNASCN1ASCN2ASCN3A
SCHEMBL8184959 0.87 EBP (0.54) MAPTLMNASCN1ASCN2ASCN3A
SCHEMBL29625647 0.87 EBP (0.54) MAPTLMNASCN1ASCN2ASCN3A
SCHEMBL5410731 0.86 LMNA (0.78) MAPTLMNASCN1ASCN2ASCN3A
Hydrochloric Acid SCHEMBL11672435 0.85 LMNA (0.76) MAPTLMNASCN1ASCN2ASCN3A
SCHEMBL250102 0.84 EBP (0.69) MAPTLMNASCN1ASCN2ASCN3A
SCHEMBL2953908 0.84 MAPT (0.74) MAPTRAB9ABCHEACHEESR1
SCHEMBL3149568 0.84 EBP (0.69) MAPTLMNASCN1ASCN2ASCN3A
SCHEMBL1951546 0.83 MAPT (1.00) MAPTLMNARAB9AKMT2AKDM4E
SCHEMBL10885211 0.83 EBP (0.71) MAPTLMNASCN1ASCN2ASCN3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4642766-A1 COMPOUNDS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-11-05 EP disclosed
US-12404243-B2 Inhibitors of the Wnt/beta-catenin pathway THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-09-02 US disclosed
EP-3749640-B1 INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY UNIV CALIFORNIA (US) 2025-07-16 EP disclosed
WO-2024145585-A1 COMPOUNDS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-07-04 WO disclosed
US-20240059654-A1 INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2024-02-22 US disclosed
US-11708329-B2 Inhibitors of the WNT/beta-catenin pathway THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-07-25 US disclosed
US-20210371384-A1 INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-02 US disclosed
EP-3749640-A1 INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY The Regents of the University of California (US) 2020-12-16 EP disclosed
WO-2019152536-A1 INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-08-08 WO disclosed
US-7582655-B2 1-[4-(2-Dimethylaminoethoxy)phenylcarbonyl]-3,5-bis(phenylmethylene)-4-piperidone hydrochloride; useful in reversing multidrug resistance UNIVERSITY OF SASKATCHEWAN (CA) 2009-09-01 US disclosed
EP-1960358-A1 ANTINEOPLASTIC COMPOUNDS University of Saskatchewan (CA) 2008-08-27 EP disclosed
US-20070155733-A1 1-[4-(2-Dimethylaminoethoxy)phenylcarbonyl]-3,5-bis(phenylmethylene)-4-piperidone hydrochloride; useful in reversing multidrug resistance UNIVERSITY OF SASKATCHEWAN (CA) 2007-07-05 US disclosed
WO-2007059613-A1 ANTINEOPLASTIC COMPOUNDS UNIVERSITY OF SASKATCHEWAN (CA) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708329-B2 Inhibitors of the WNT/beta-catenin pathway CTNNB1, CTNNBL1, CTNND1 MAPT 3908/4885LMNA 3371/4885SCN1A 4309/4885
US-12404243-B2 Inhibitors of the Wnt/beta-catenin pathway CTNNB1, CTNNBL1, CTNND1 MAPT 3908/4885LMNA 3371/4885SCN1A 4309/4885
US-20210371384-A1 INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY CTNNB1, CTNNBL1, CTNND1 MAPT 3908/4885LMNA 3371/4885SCN1A 4309/4885
US-20070155733-A1 1-[4-(2-Dimethylaminoethoxy)phenylcarbonyl]-3,5-bis(phenylmethylene)-4-piperidone hydrochloride; useful in reversing multidrug resistance ABCC1, MCL1, SLC11A2 MAPT 4706/4885LMNA 1083/4885SCN1A 1068/4885
US-20240059654-A1 INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY CTNNB1, CTNNBL1, CTNND1 MAPT 3908/4885LMNA 3371/4885SCN1A 4309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.